Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis (PROMETHEE)
Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis, With Analysis of CD4 + Follicular Helper T Subpopulations
Sponsor: Rennes University Hospital
This NA trial investigates Rheumatoid Arthritis and is currently completed. Rennes University Hospital leads this study, which shows 8 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2023 — Jul 2024 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2021 — Feb 2023 [monthly]
Unknown Status NA
-
Jun 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — Jun 2020 [monthly]
Recruiting NA
-
Jun 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Jun 2017 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rennes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .